Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2200/00—Function of food ingredients
  • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
  • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2250/00—Food ingredients
  • A23V2250/02—Acid
  • A23V2250/05—Propionic acid

Definitions

• the invention relates to an agent for the prophylactic and / or supportive therapeutic treatment of Parkinson's disease.
• the microbiome of the intestine can be influenced by the type of food and is able to adapt to the requirements of the respective food. This means that a gut flora that is unfavorable to the patient's immune status can be changed by dietary measures to improve the immune status of the patient.
• the invention is based on the finding that in Parkinson's disease a characteristic change of the microbiome in comparison to healthy controls.
• short-chain fatty acids producing bacteria are hardly or not present in the microbiome. Accordingly, there is a shortage of short-chain fatty acids that occur in the gut of a healthy control person as degradation products. Braak has postulated that the disease
• Parkinson's begins in the gut. This is consistent with the finding that the transfer of the microbiome from Parkinson's disease mice to healthy mice causes Parkinson's disease to be comparable.
• Alpha-synuclein a transport protein that occurs in the brain and plays a role in Parkinson's disease, can be found in very early stages
• the invention relates to an agent for use in the prophylactic and / or adjunctive therapeutic treatment of Parkinson's disease containing a physiologically effective amount of propionic acid and / or butyric acid and / or their physiologically acceptable salts or esters.
• the agent according to the invention can be administered both for prophylactic and for therapeutic purposes to persons who have a predisposition to Parkinson's disease, or to Parkinson's patients.
• the agent is suitable for the supportive therapeutic treatment of Parkinson's patients, who otherwise undergo conventional drug treatment.
• the agent of the invention may contain propionic acid or butyric acid each alone or in combination as such.
• the administration in the form of the physiologically acceptable salts is preferred, with the salts of physiologically important metals in the foreground.
• propionic and butyric acids can also be administered in the form of their esters.
• Particularly suitable here are the esters of C 1 to C 6 alcohols, in particular the methyl and ethyl esters.
• the esters are hydrolyzed in the body to free acids.
• the agent according to the invention can be administered in conventional forms, for example in the form of tablets, dragees, pills, capsules, troches, powders and granules. Administration in liquid form is also possible in the form of juices, drops and teas. In any case, the agent for oral intake is determined.
• Preferred administration forms are tablets, capsules and powders.
• the tablets and capsules containing a unit dose of the agent according to the invention are preferably administered twice a day.
• the powder can be stirred into a drink, for example, or else added to the food.
• a unit dose for the above-mentioned administration forms is in the range of 0.2 to 5 g, especially 0.3 to 3 g.
• a particularly preferred amount for tablets, capsules and powders is 0.5 to 2.0 g, each intended for morning and evening administration, optionally also additionally on a daily basis, in particular in connection with the meals.
• the weight ratio may be, for example, in the range from 3: 1 to 1: 3, in particular 3: 2 to 2: 3, in the case of the total doses indicated above.
• the agent according to the invention can be used for the supportive therapeutic treatment of Parkinson's patients.
• it is given in addition to the usual drug treatment, for example together with levodopa and other dopaminergic drugs, as they are commonly used.
• the dosage of the agent according to the invention is as indicated above.
• butyric acid / butyrate The effect of butyric acid / butyrate was studied in patient studies in which more than 1, 000 subjects have participated for at least one year. A total of 6 g of butyric acid or butyrate (as a salt) together with the medically prescribed medication (levodopa and others) were administered in three daily doses in the morning, at noon and in the evening with meals. There were significant improvements in the general condition, especially in the motor, found. Surprisingly, it was found that the dopamine requirement of butyric acid / butyrate-treated Parkinson's patients had decreased by at least 50%, in some cases by up to 90%. This is of particular importance because the usual in Parkinson's medication not only leads to significant side effects with levodopa, such as dizziness, nausea, tachyarrhythmia, psychosis, dyskinesia, circulatory problems.
• levodopa the usual in Parkinson's medication not only leads to significant side effects with levodopa, such as di
• the invention relates to a dietary supplement containing propionic acid and / or butyric acid, the physiologically acceptable salts or esters thereof alone or as a mixture. Preference is given to butyric acid or a butyrate, optionally together with propionic acid or a propionate, in particular in capsule or tablet form.
• the dietary supplement in capsule or tablet form preferably contains propionic and butyric acid in the form of one salt each.
• the weight ratio is in particular 3: 1 to 1: 3, with a total amount of 0.5 to 2.0 g.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Psychology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Inorganic Chemistry (AREA)
• Polymers & Plastics (AREA)
• Nutrition Science (AREA)
• Food Science & Technology (AREA)
• Mycology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=63108510

Family Applications (1)

Country Status (10)

Cited By (2)

Families Citing this family (1)

Citations (3)

Family Cites Families (6)

• 2017
  • 2017-07-13 DE DE102017115819.7A patent/DE102017115819A1/de not_active Withdrawn
• 2018
  • 2018-07-13 US US16/627,688 patent/US20200163914A1/en not_active Abandoned
  • 2018-07-13 AU AU2018298862A patent/AU2018298862A1/en not_active Abandoned
  • 2018-07-13 JP JP2019571280A patent/JP7206223B2/ja active Active
  • 2018-07-13 CA CA3067728A patent/CA3067728A1/en active Pending
  • 2018-07-13 EP EP18750103.6A patent/EP3651754B1/de active Active
  • 2018-07-13 WO PCT/EP2018/069089 patent/WO2019012108A1/de not_active Ceased
  • 2018-07-13 KR KR1020207003431A patent/KR20200027976A/ko not_active Ceased
  • 2018-07-13 CN CN201880042374.6A patent/CN110996933A/zh active Pending
  • 2018-07-13 BR BR112020000570-3A patent/BR112020000570A2/pt not_active Application Discontinuation
• 2021
  • 2021-11-26 AU AU2021273627A patent/AU2021273627B2/en active Active
• 2022
  • 2022-06-20 US US17/807,797 patent/US20220313634A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events